Boryung, Lotus Pharma signs CDMO deal on anticancer injection

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and manufacturing organization (CDMO) to cytotoxic drugs. 

Under the agreement, Boryung will manufacture an anticancer injection for Lotus. 

The company plans to supply the agent to Lotus starting in 2026. 

The product name will be disclosed by agreement between the two companies.

Boryung will manufacture the anticancer drug at its EU-GMP-certified plant in Yesan, South Chungcheong Province.

The facility, designed by Novo Nordisk Engineering (NNE), can produce 6 million vials annually. 

Write to Ji-Hyun Lee at bluesky@hankyung.com